Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.62 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21570750 | 0.85 | NTRK1 (0.52) | NTRK1NTRK3JAK2 | |
| SCHEMBL20119444 | 0.85 | NTRK1 (0.61) | NTRK1JAK2 | |
| SCHEMBL20119922 | 0.85 | NTRK1 (0.61) | NTRK1JAK2 | |
| SCHEMBL21313078 | 0.82 | NTRK1 (0.72) | NTRK1NTRK3JAK2 | |
| SCHEMBL20119386 | 0.82 | NTRK1 (0.72) | NTRK1NTRK3JAK2 | |
| SCHEMBL21319540 | 0.80 | NTRK1 (0.56) | NTRK1JAK2 | |
| SCHEMBL23070650 | 0.77 | NTRK1 (1.00) | NTRK1NTRK3JAK2 | |
| SCHEMBL30304289 | 0.74 | NTRK1 (0.80) | NTRK1JAK2 | |
| SCHEMBL933772 | 0.74 | NTRK1 (0.81) | NTRK1JAK2 | |
| SCHEMBL933774 | 0.74 | NTRK1 (0.81) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533796-B1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3533796-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018077246-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | 正大天晴药业集团股份有限公司 | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | NTRK2, BDNF, NTRK1 | NTRK1 3/4885NTRK3 5/4885JAK2 291/4885 |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | NTRK2, BDNF, NTRK1 | NTRK1 3/4885NTRK3 5/4885JAK2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.